Addex Therapeutics Ltd (ADXN)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Addex Therapeutics Ltd (ADXN) trades at $6.70 with AI Score 44/100 (Weak). Addex Therapeutics Ltd is a development-stage biopharmaceutical company focused on discovering and developing small-molecule pharmaceuticals for central nervous system (CNS) disorders. Market cap: 5M, Sector: Healthcare.
Last analyzed: Mar 15, 2026Addex Therapeutics Ltd (ADXN) Healthcare & Pipeline Overview
Addex Therapeutics Ltd, based in Switzerland, is a biopharmaceutical company specializing in the discovery and development of small-molecule allosteric modulators for central nervous system disorders, positioning itself within the competitive biotechnology sector with a focus on unmet medical needs.
Investment Thesis
Addex Therapeutics presents a high-risk, high-reward investment profile typical of development-stage biopharmaceutical companies. The company's value hinges on the successful clinical development and eventual commercialization of its lead drug candidates, particularly Dipraglurant for Parkinson's disease LID and dystonia. Positive Phase 2b trial results for Dipraglurant could serve as a significant catalyst, potentially leading to increased investor interest and partnership opportunities. However, the company's small size (2 employees) and limited financial resources pose significant risks. The negative profit margin of -4397.0% underscores the company's reliance on external funding and partnerships. The high beta of 1.91 suggests significant volatility relative to the broader market. Investors should carefully weigh the potential upside against the inherent risks associated with drug development and commercialization.
Based on FMP financials and quantitative analysis
Key Highlights
- Addex Therapeutics focuses on small-molecule allosteric modulators of G-protein coupled receptors (GPCRs) for CNS disorders.
- Lead programs include Dipraglurant for Parkinson's disease levodopa-induced dyskinesia (LID) and dystonia.
- The company has a negative profit margin of -4397.0%, reflecting its development-stage status and reliance on external funding.
- Gross margin is -14.1%, indicating that the cost of revenue exceeds revenue generated.
- Beta is 1.91, suggesting higher volatility compared to the overall market.
Competitors & Peers
Strengths
- Proprietary allosteric modulation technology.
- Focus on CNS disorders with unmet needs.
- Strategic partnerships with pharmaceutical companies.
- Lead programs in clinical development.
Weaknesses
- Limited financial resources.
- Small size and limited infrastructure.
- Reliance on external funding and partnerships.
- High R&D costs and regulatory hurdles.
Catalysts
- Upcoming: Phase 2b trial results for Dipraglurant in Parkinson's disease LID and dystonia (timeline: Unknown).
- Upcoming: Potential new partnerships or licensing agreements (timeline: Unknown).
- Ongoing: Advancement of ADX71149 through clinical trials for epilepsy (timeline: Ongoing).
- Ongoing: Continued research and development of GABAB PAM for addiction treatment (timeline: Ongoing).
Risks
- Potential: Clinical trial failures for lead drug candidates.
- Potential: Regulatory setbacks and delays.
- Ongoing: Limited financial resources and reliance on external funding.
- Ongoing: Competition from other pharmaceutical companies.
- Potential: Patent expirations and intellectual property challenges.
Growth Opportunities
- Expansion of Dipraglurant's Clinical Development: A key growth opportunity lies in advancing Dipraglurant through late-stage clinical trials for Parkinson's disease LID and dystonia. Positive results in Phase 2b trials could unlock significant value, attracting potential partners and paving the way for regulatory approval. The market for Parkinson's disease treatments is projected to reach billions of dollars, offering substantial revenue potential if Dipraglurant proves effective and safe.
- Advancement of ADX71149 for Epilepsy: Progressing ADX71149 through clinical trials for epilepsy and other CNS disorders represents another growth avenue. Epilepsy affects millions worldwide, creating a significant market opportunity for novel therapies. Successful development and commercialization of ADX71149 could diversify Addex's product pipeline and revenue streams.
- Partnerships and Licensing Agreements: Addex can leverage strategic partnerships and licensing agreements to accelerate drug development and commercialization. Collaborations with larger pharmaceutical companies can provide access to funding, expertise, and global distribution networks. Expanding existing partnerships and forging new alliances will be crucial for Addex's long-term growth.
- Expansion into New Therapeutic Areas: Addex could explore expanding its research and development efforts into new therapeutic areas within CNS disorders. Identifying and targeting novel mechanisms and pathways could lead to the discovery of innovative therapies for conditions with unmet medical needs. This diversification strategy could reduce reliance on existing programs and broaden the company's market reach.
- GABAB PAM for Addiction Treatment: Developing GABAB PAM for addiction treatment presents a significant growth opportunity. Addiction is a major public health problem with limited treatment options. Successful development and commercialization of GABAB PAM could address a critical unmet need and generate substantial revenue. The addiction treatment market is expected to grow significantly in the coming years, driven by increasing awareness and demand for effective therapies.
Opportunities
- Advancement of lead programs through clinical trials.
- Expansion into new therapeutic areas.
- Strategic collaborations and licensing agreements.
- Growing market for CNS disorder treatments.
Threats
- Clinical trial failures.
- Regulatory setbacks.
- Competition from other pharmaceutical companies.
- Patent expirations.
Competitive Advantages
- Proprietary allosteric modulation technology platform.
- Strong intellectual property protection for drug candidates.
- Strategic partnerships with established pharmaceutical companies.
- Focus on underserved markets within CNS disorders.
About ADXN
Founded in 2002, Addex Therapeutics Ltd is a Swiss biopharmaceutical company dedicated to discovering, developing, and commercializing small-molecule pharmaceutical products for central nervous system (CNS) disorders. The company's core focus lies in allosteric modulation, particularly of G-protein coupled receptors (GPCRs), using oral small molecule drugs. This approach aims to create novel treatments for conditions with significant unmet medical needs. Addex's lead programs include Dipraglurant, targeting Parkinson's disease levodopa-induced dyskinesia (LID) and dystonia; ADX71149, for epilepsy and other undisclosed CNS disorders; and GABAB PAM, aimed at treating addiction. Addex operates primarily out of its headquarters in Geneva, Switzerland. The company has established strategic collaborations and licensing agreements with pharmaceutical companies such as Janssen Pharmaceuticals Inc. and Indivior PLC, as well as with organizations like The Charcot-Marie-Tooth Association. These partnerships are crucial for funding research, development, and potential commercialization of its drug candidates. Addex Therapeutics Ltd was originally known as Addex Pharmaceuticals Ltd and rebranded in March 2012 to reflect its evolving focus on therapeutics.
What They Do
- Discovers small-molecule pharmaceutical products.
- Develops treatments for central nervous system (CNS) disorders.
- Focuses on allosteric modulators of G-protein coupled receptors (GPCRs).
- Develops oral small molecule drugs.
- Targets Parkinson's disease levodopa-induced dyskinesia (LID) and dystonia with Dipraglurant.
- Develops ADX71149 for epilepsy and undisclosed CNS disorders.
- Develops GABAB PAM for addiction treatment.
Business Model
- Discovers and develops novel drug candidates for CNS disorders.
- Out-licenses or partners with larger pharmaceutical companies for clinical development and commercialization.
- Generates revenue through licensing fees, milestone payments, and royalties on sales of partnered products.
Industry Context
Addex Therapeutics operates within the competitive biotechnology industry, which is characterized by high R&D costs, lengthy development timelines, and significant regulatory hurdles. The market for CNS disorder treatments is substantial and growing, driven by an aging population and increasing prevalence of conditions like Parkinson's disease, epilepsy, and addiction. Addex's focus on allosteric modulation offers a potentially differentiated approach compared to traditional drug development methods. Competitors like ADIL, BCLI, CDIO, IBO, and MTNB are also pursuing novel therapies for neurological disorders, creating a dynamic and challenging competitive landscape.
Key Customers
- Pharmaceutical companies (through licensing and collaboration agreements).
- Patients suffering from CNS disorders (indirectly, through commercialized drugs).
- Healthcare providers (indirectly, through prescription and administration of drugs).
Financials
Chart & Info
Addex Therapeutics Ltd (ADXN) stock price: $6.70 (+0.40, +6.35%)
Latest News
-
12 Health Care Stocks Moving In Thursday's Pre-Market Session
benzinga · Mar 19, 2026
-
Short Interest in Addex Therapeutics Ltd. Sponsored ADR (NASDAQ:ADXN) Expands By 137.6%
defenseworld.net · Mar 14, 2026
-
12 Health Care Stocks Moving In Wednesday's After-Market Session
benzinga · Mar 11, 2026
-
Addex's Preclinical Data Published In Molecular Psychiatry Highlights mGlu7 Negative Allosteric Modulators As Promising Therapy For PTSD And Anxiety
benzinga · Feb 3, 2026
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for ADXN.
Price Targets
Wall Street price target analysis for ADXN.
MoonshotScore
What does this score mean?
The MoonshotScore rates ADXN's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Competitors & Peers
Latest News
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Short Interest in Addex Therapeutics Ltd. Sponsored ADR (NASDAQ:ADXN) Expands By 137.6%
12 Health Care Stocks Moving In Wednesday's After-Market Session
Addex's Preclinical Data Published In Molecular Psychiatry Highlights mGlu7 Negative Allosteric Modulators As Promising Therapy For PTSD And Anxiety
Leadership: Timothy Mark Dyer
Managing Director
Timothy Mark Dyer serves as the Managing Director of Addex Therapeutics Ltd. His background includes experience in the pharmaceutical and biotechnology industries, with a focus on corporate strategy, business development, and financial management. He is responsible for overseeing the company's operations, strategic direction, and financial performance. Dyer's leadership is crucial for navigating the challenges of a development-stage biopharmaceutical company.
Track Record: Under Timothy Mark Dyer's leadership, Addex Therapeutics has focused on advancing its lead programs through clinical development and securing strategic partnerships. Key milestones include progressing Dipraglurant towards Phase 2b trials and maintaining collaborations with companies like Janssen Pharmaceuticals and Indivior PLC. His tenure has been marked by efforts to secure funding and manage the company's limited resources effectively.
Addex Therapeutics Ltd ADR Information Sponsored
An American Depositary Receipt (ADR) is a certificate representing shares of a foreign company that are held by a U.S. depositary bank. ADXN, as an ADR, allows U.S. investors to trade shares of Addex Therapeutics, a Swiss company, on U.S. exchanges, simplifying cross-border investing.
- Home Market Ticker: SIX Swiss Exchange, Switzerland
- ADR Level: 2
- ADR Ratio: 1:1
What Investors Ask About Addex Therapeutics Ltd (ADXN)
What does Addex Therapeutics Ltd do?
Addex Therapeutics Ltd is a biopharmaceutical company focused on discovering and developing small-molecule pharmaceuticals for central nervous system (CNS) disorders. The company's core technology revolves around allosteric modulation of G-protein coupled receptors (GPCRs). Their lead programs target conditions like Parkinson's disease, epilepsy, and addiction. Addex aims to create novel treatments by modulating GPCRs, offering a potentially differentiated approach compared to traditional drug development methods. The company primarily operates through partnerships and licensing agreements with larger pharmaceutical firms.
What do analysts say about ADXN stock?
As a development-stage biopharmaceutical company, Addex Therapeutics' stock performance is highly dependent on clinical trial outcomes and regulatory milestones. Given the company's negative profit margin and reliance on external funding, valuation is challenging. Analyst sentiment is likely to be influenced by progress in the company's lead programs, particularly Dipraglurant. Investors should closely monitor clinical trial results and partnership developments to assess the potential upside and downside risks.
What are the main risks for ADXN?
The primary risks for Addex Therapeutics include clinical trial failures, regulatory setbacks, and financial constraints. As a development-stage company, Addex is heavily reliant on the successful development and commercialization of its drug candidates. Clinical trial failures or regulatory delays could significantly impact the company's value. Additionally, Addex's limited financial resources and reliance on external funding pose ongoing risks. Competition from larger pharmaceutical companies with greater resources also presents a challenge.
What are the key factors to evaluate for ADXN?
Addex Therapeutics Ltd (ADXN) currently holds an AI score of 44/100, indicating low score. Key strength: Proprietary allosteric modulation technology.. Primary risk to monitor: Potential: Clinical trial failures for lead drug candidates.. This is not financial advice.
How frequently does ADXN data refresh on this page?
ADXN prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven ADXN's recent stock price performance?
Recent price movement in Addex Therapeutics Ltd (ADXN) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Proprietary allosteric modulation technology.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider ADXN overvalued or undervalued right now?
Determining whether Addex Therapeutics Ltd (ADXN) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying ADXN?
Before investing in Addex Therapeutics Ltd (ADXN), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on publicly available sources and may be subject to change.
- Investment in development-stage biopharmaceutical companies involves significant risks.